Introduction 1
Patients may require long-term administration of potentially veinotoxic compounds due to 2 chronic conditions such as solid tumors, hematologic malignancies, digestive diseases, cystic 3 fibrosis (CF) or infection with human immunodeficiency virus (HIV). 1,2 Long-term 4 intravascular catheters (LTIVC) were developed to reduce the associated toxicity and risk of 5 bacterial or fungal colonization due to the subcutaneous route or "tunnel" that impedes the 6 migration of microorganisms present on the surface of the skin. 3, 4 In the early 80's, an initial 7 report described the use of a new type of LTIVC called a totally implantable venous access 8 port (TIVAP). 5 TIVAP is composed of a subcutaneously implanted port (or reservoir) 9 connected to a central venous catheter, most frequently inserted into the internal jugular, 10 subclavian or cephalic vein. 2 Use of TIVAPs is now a standard clinical practice and has 11 significantly increased patients' comfort and quality of life, as compared to other LTIVCs. 2 12
TIVAPs are inserted for the administration of antineoplastic chemotherapy, parenteral 13 nutrition, blood products and for prolonged antimicrobial treatment in CF. 2, 6, 7 The number of 14
implanted TIVAPs is increasing and more than 400,000 of them are sold each year in the 15 USA. 8 Despite a reduction of the risk of microbial contamination due to total implantation 16 under the skin, 3 to 10% of TIVAP carriers experience a related infection which is the most 17 common indication for TIVAP removal, illustrating the impact of this complication on patient 18 care and the necessity for focused research in this area. 9-14 19 This review aims to provide insights into challenges associated with TIVAP-related 20 infections, including diagnosis, prevention, and novel approaches that may improve patients' 21 management. 22 23 24 5
Epidemiology reflects risk factors and routes of colonization 1
Depending on the indication for TIVAP insertion, patients are exposed to different risk 2 factors and therefore exhibit different infection rates. For instance, if TIVAP is inserted for 3 antineoplastic chemotherapy or in CF patients, the incidence density of infection ranges from 4 0·11 to 0·37/1,000 catheter-days. 6, 9, 10, [13] [14] [15] [16] [17] In cancer patients, the risk of TIVAP-related 5 infection appears to remain unchanged with incidence densities of 0·21 and 0·20/1,000 6 catheter-days reported in 1993 and 2011, respectively. 9,13 7
If TIVAP is used for total parenteral nutrition (TPN), incidence density of infection is higher 8 and is comprised between 0·33 and 3·2/1000 catheter-days with heterogeneous data 9 depending on the indication for TPN. 7, 18, 19 In HIV-infected patients, incidence density ranges 10 from 1·5 to 3·81/1,000 catheter-days, probably because when a LTIVC is required, these 11 patients combine most of the risk factors of infection identified so far. 20, 21 The reported time 12
to infection from TIVAP insertion ranges from 80 to 192 days with extreme values of 2 and 13 1406 days. 10,13,20,21 14 These discrepancies between patient groups probably reflect exposure towards different risk 15 factors and TIVAP handling frequency. Indeed, a prospective study demonstrated that the 16 frequency of LTIVC handling (including about 50% of TIVAP) was associated with infection 17 incidence. 21 Additional risk factors are described in Panel 1. 18
Since frequency of TIVAP handling is one of the major risk factor identified, it is not 19 surprising to observe that coagulase-negative staphylococci (CoNS), which are frequent 20 colonizers of the human skin and mucosal flora, are one of the leading pathogens responsible 21 for TIVAP-related infections. 22 For instance, among 29 cases of TIVAP-related infections, a 22 majority of infections (57%) were caused by CoNS, other microorganisms being Gram-23 negative rods (GNR) (20%), S. aureus (7%) and C. albicans (3%). 13 More recent studies 24 described a higher rate of GNR (up to 40%) and yeasts (up to 23%). 10, 20, 23 This shift may be 25 explained by different factors such as antineoplastic chemotherapy intensification with more 26 sustained neutropenia allowing translocation of microorganisms from the gut to bloodstream, 27 besides more frequent use of TPN and broad-spectrum antibiotics. 10 To note, early TIVAP-28 related infections (≤30 days) are more frequently caused by S. aureus than late infections 29 (50% vs.12%, respectively). 24 30
Regarding antibiotic resistance, a French cohort of cancer patients reported that 58% of CoNS 31 and 25% of S. aureus were methicillin-resistant (MR). 24 MR is more frequent in the USA as 32 suggested by data reported by the National Healthcare Safety Network and also in a study of 33 6 S. aureus catheter-related bloodstream infection (CRBSI) in cancer patients, with 37 to 55% 1 of S. aureus being MR. 25,26 2 As TIVAPs are totally implanted, risk of extraluminal colonization is low and mostly occurs 3 during TIVAP insertion, resulting in surgical site infection. Once the device is inserted, 4 contamination may occur during repeated punctures with Huber needles, if the skin has not 5 been completely cleaned, therefore leading to an intraluminal colonization that can spread 6 from the port to the catheter tip. [27] [28] [29] In case of BSI coming from another focus of infection, 7 bacteria may adhere on the catheter tip, therefore defining a hematogenous route of 8 colonization, which is rare except in case of S. aureus. After device contamination, bacteria 9 adhere to the internal or external surface of TIVAP, depending on the source of 10 contamination, using proteinaceous stalks called adhesins. 30 11 Bacterial adhesion is influenced by the type of catheter material, bacterial characteristics or by 12 the presence of a layer of blood components. Indeed, once an indwelling device is inserted, a 13 conditioning film made of host components like fibrin or platelets covers it. 27, 31 These 14 deposits may enhance or inhibit bacterial adhesion besides reducing the efficacy of any 15 antibiotic-releasing surface. After several days, all catheters get covered by a fibrin sheath. 32 16
Following adhesion, bacteria multiply and constitute a surface-associated microbial 17 community called a biofilm, which is embedded in a matrix of extracellular polymeric 18 substances produced by both bacteria and the host. 11,30 Biofilm bacteria exhibit tolerance 19 defined as the ability to survive high concentrations of antibiotics. 33 Thus, systemic 20 antibiotics can cure TIVAP-related BSI but the source of infection cannot be eradicated 21 unless the device is removed or intraluminal treatment used. This high tolerance is 22 responsible for infection relapse with the same pathogen. Preventive approaches are therefore 23 pivotal in order to avoid any microbial contamination and subsequent biofilm formation. 24 25 26
Preventive strategies to reduce risks of colonization 1
Because of a reduced risk of infection, TIVAPs are favored over other LTIVCs for use in 2 treatment of solid tumor and pediatric hematology patients. 13, 23, 34 In case of prolonged TPN, 3 due to a higher risk of infection associated with TIVAPs, a tunnelled catheter may be 4 preferred if daily vascular access is required. 1,7 If TIVAP is chosen in oncology or 5 hematology patients, it should be inserted as early as possible, due to increased risk of 6 infection in case of neutropenia. 35, 36 Then, preventive strategies must be applied during and 7 after TIVAP insertion. 8 9
Preventive measures during TIVAP insertion 10
Trained personnel with maximum sterile barrier precautions, including sterile gloves, cap, 11 mask, sterile gown and a sterile full body drape, must perform TIVAP insertion. 2,37,38 For skin 12 preparation, alcohol-based chlorhexidine or alcohol-based povidone-iodine should be used at 13 least 30 seconds and left to dry, as suggested by recent Infectious Diseases Society of 14 America (IDSA) guidelines. 38 Chlorhexidine concentration should be >0·5% (usually 2% in 15 clinical trials) with alcohol. Although recommended in France, skin cleaning (or scrubbing) 16 before antiseptic application is still debated. 39 Furthermore, no randomized, prospective 17 clinical trial has directly compared the two alcohol-based antiseptic solutions, therefore 18 advocating a comparative study. 39 
19
The choice of venipuncture site is not associated with different infection rates as 20 demonstrated by a prospective study of 403 patients randomly allocated to an internal jugular 21 vein or subclavian vein insertion, or a surgical cut-down through the cephalic vein. 40 If the 22 superior vena cava is not accessible -for instance due to thrombosis -TIVAP can be inserted 23 in the femoral vein with an infection incidence of 0·69/1,000 catheter-days, as reported 24 among 20 cancer patients. 41 Use of ultrasound guidance for catheter insertion has not been 25 shown to reduce the rate of TIVAP-related infections but significantly reduces the number of 26 attempts and increases patient comfort. 40, 42 Systemic antibiotic prophylaxis has no 27 demonstrated benefit during TIVAP insertion and is not indicated. 43-45 28 29
Preventive measures after TIVAP insertion 30
Training of patients, nursing teams and physicians is mandatory to minimize the risk of 31 bacterial contamination. 7 The Huber needle used to access the TIVAP must be inserted by 32 trained nurses and requires that operators wear a facial mask, a cap and use sterile gloves. 33
Skin disinfection must be performed with an alcoholic antiseptic, prior to each needle 34 8 insertion (see above). 38 The Huber needle can be changed every seven days if vascular access 1 is maintained continuously. 10 During needle withdrawal, an experimental study suggested that 2 positive pressure using saline injection reduces the risk of blood reflux, therefore preventing 3 catheter tip occlusion. 46 It is now recommended that heparin lock or flush after TIVAP use 4
should not be performed, as sterile saline locks are equally efficient to prevent functional or 5 infectious complications. 38, 47 Even if different studies demonstrated the benefits of 6 chlorhexidine-impregnated sponges or dressings for the prevention of CRBSI in intensive 7 care units, no studies including TIVAP have been published. 8 9
Lock solutions and coatings to prevent TIVAP-related infections 10
The principle of preventive antibiotic lock therapy (ALT) is to inject highly concentrated 11 antibiotic solution inside the TIVAP lumen. This solution dwells for extended time periods in 12 order to eradicate any bacteria that might get injected inside TIVAP due to incomplete skin 13 antisepsis. Preventive ALT can thus only prevent intraluminal contamination. The chosen 14 volume must allow coverage of the whole internal surface and therefore depends on the type 15 of device. A meta-analysis demonstrated that ALT or antibiotic flush made of vancomycin 16 reduced the risk of CRBSI. 48 Other groups have assessed the combination of antibiotic 17 (minocycline) and a chelator such as ethylene diamine tetra-acetic acid (EDTA). 49 Two 18 studies in the pediatric oncology setting have shown that minocyline-EDTA ALT was more 19 effective than heparin for the prevention of CRBSI. 50,51 Nevertheless, systematic use of ALT 20 could lead to increased antibiotic resistance. 31,52 Thus, recent IDSA guidelines recommend to 21 restrict the use of preventive ALT to patients with LTIVC who experienced multiple CRBSI 22 despite optimal aseptic techniques. 38 
23
Limited data are available for non-antibiotic lock solutions, such as ethanol-or taurolidine-24 locks. One preliminary pediatric study using ethanol locks including 12 patients with TIVAP 25 was interrupted as 3 patients experienced TIVAP occlusion. 53 A meta-analysis showed that 26 ethanol lock therapy reduces the incidence of CRBSI in pediatric TPN with tunnelled 27 catheters but increases the risk of thrombosis. 54 Therefore, ethanol lock could be proposed in 28 cases of high-risk TPN patients with tunnelled catheters. 55 Mild and self-limited adverse 29 effects have been reported, especially after flushing the lock, such as dizziness, nausea, 30 headaches, facial flushing and, eventually, an alcohol taste in the mouth. 56,57 31
Taurolidine, a derivative from of the amino acid taurine, was proposed as a lock therapy in 32 1993 because of its antimicrobial effect against a broad range of microorganisms in vitro. 58-60 33 Although studies conducted in hemodialysis patients are encouraging, data supporting its use 34 as a lock in TIVAP are limited. 61, 62 In pediatric cancer patients, an initial study showed no 1 significant reduction of CRBSI with taurolidine/citrate as compared to heparin, with ~75% of 2 TIVAP patients amongst LTIVC. 63 A more recent study in pediatric hematology patients 3 showed a significant reduction of CRBSI with taurolidine/citrate as compared to heparin but 4 included only tunnelled catheters. 59 A randomized study in TPN patients demonstrated that 5 taurolidine/citrate reduced the rate of CRBSI when initiated after the first episode of 6 infection, as compared with heparin (TIVAP represented ~ 40% of LTIVC). 64 Based on these 7 results, larger comparative studies with TIVAP are needed to define the precise role and 8
indications of ethanol or taurolidine as preventive locks. 9
The use of CVC coatings has been extensively studied in case of short-term CVC, leading to a 10 significant reduction of the risk of CRBSI. 65, 66 As LTIVCs dwell for a longer time in the 11 blood flow, the formation of the conditioning film reduces the antimicrobial action of the 12 coating. 27 Furthermore, in case of antibiotic-releasing surfaces, the effect will stop once the 13 device is exhausted. A single study assessed LTIVC coated with minocycline/rifampin but 14 with a relatively short catheterization time period (mean duration of 66±31 days) and reported 15 a significant reduction of CRBSI. 67 Clinically significant drug delivery was maintained at 16 least 35 days post catheter insertion. Thus, developing an efficient surface modification or 17 antibiotic coating that would help preventing colonization is still a major challenge (see 18 "Future Treatments" section). 19 20 21
Diagnosis of TIVAP-related infections 1
TIVAP-related infection is easily suspected if the patient exhibits local signs such as pain or 2 erythema at the site of TIVAP implantation. However, diagnosis is more difficult in case of 3 isolated fever, chills or severe sepsis. Recent IDSA guidelines have proposed three classes of 4 TIVAP-related infections: 68 5 -Local complicated infections, defined as a tunnel or port-pocket infection with extended 6 erythema or induration (more than two cm), purulent collection, skin necrosis and 7 spontaneous rupture and drainage ( Figure 1A ). 68 8 -TIVAP-related BSI, defined as a positive blood culture drawn from a peripheral vein 9 associated with evidence that the BSI originates from the TIVAP using paired blood cultures 
Diagnosis of TIVAP-related BSI without device removal 29
This diagnosis relies on the identification of the same microorganism in paired blood 30 cultures. 68 Correct interpretation of the test requires blood samples to be performed 31 consecutively, with the same volume of blood drawn from a peripheral vein and from the 32 TIVAP through a Huber needle, ideally before the initiation of antimicrobials. 68, 72, 73 Another 33 critical point is to precisely label the origin of each blood culture bottle. 68 The two most 34 commonly used methods for diagnosing CRBSI are simultaneous quantitative blood cultures 1 and the differential time to positivity (DTP) of qualitative blood cultures. 72,74-76 If TIVAP is 2 the source of BSI, the inoculum will be higher in the blood drawn from TIVAP, as compared 3 with peripheral vein, therefore leading to a shorter time to positivity (difference ≥ two hours) 4 or a higher bacterial quantification (≥four-fold). 68, 72, 73, 75, 76 When used for the diagnosis of 5 LTIVC-related BSI, these two methods have sensitivity above 90% and specificity close to 6 100% and between 75% and 91% for quantitative paired blood cultures and DTP, 7 respectively. 72,75,76 They are nevertheless considered equivalent in recent guidelines and the 8 choice of a technique will mostly rely on local equipment and training. 68 9
To reduce the risk of contamination when blood is drawn from TIVAP, a rigorous skin 10 disinfection is mandatory before sampling (see "Prevention" section). 68 11 12
Diagnosis of TIVAP-related BSI after device removal 13
The demonstration that a BSI originates from a TIVAP relies on the identification of the same 14 microorganism in a TIVAP component and peripheral blood cultures. The catheter tip (four-15 cm distal part) can be cultured using the semiquantitative or quantitative methods with 16 thresholds defining a significant colonization of >15 CFU and ≥10 3 CFU/mL, respectively 17 ( Figures 3A and B ). 77,78 Both methods can be equally used but are associated with sensitivity 18 below 50% for the diagnosis of TIVAP colonization, stressing the importance of using other 19 techniques. 68,69,71,79 For instance, it has been proposed to perform quantitative culture of the 20 TIVAP septum using an adapted Brun-Buisson method ( Figures 3A and C) . 69 With a 21 threshold of 10 3 CFU/mL, this method was associated with 93% sensitivity and 100% 22 specificity for the diagnosis of TIVAP-related BSI. 69 Furthermore, after septum removal, if 23 macroscopic debris or clots are present, they can be sampled and cultured with a sensitivity 24 and specificity of 100% in case of TIVAP-related BSI. 71 The main limitations of port septum 25 and port deposit cultures are lack of technical standardization and absence of a consensus 26 threshold. 68 . Therefore, performing both catheter tip culture and a culture of a component of 27 the port reservoir is advisable. 68 Careful handling of explanted materials will reduce the risk 28 of contamination in the clinical microbiology laboratory. 29
30

Diagnosis of fungal TIVAP-related BSI 31
Without TIVAP removal, such a diagnosis is challenging as studies assessing paired blood 32 cultures infrequently included study of fungal infections 72,74,75,80 Some authors have proposed 33 to use the time taken to detect Candida spp. growth in peripheral blood as a diagnostic tool, 34 since time to positivity is shorter in case of catheter-related (CR) candidemia (17±2h) than 1 candidemia from another source (38±3h). 81 The objective of this approach would be to rule 2 out the catheter as the source of candidemia if time to positivity is above 30 hours. In case of 3 TIVAP removal, microbiological methods and thresholds are the same, and culture on blood 4 agar is sensitive enough for the growth of fungi involved in TIVAP-related infections, even if 5 they may require a longer incubation time than bacteria (24-72h). 82 In the case of CRBSI, the treatment of choice is systemic antimicrobial therapy in conjunction 2 with removal of the colonized device. 4 However, in case of TIVAPs, reduced venous access, 3 potential presence of coagulation disorders, the need for a new procedure and its cost, all 4 argue in favor of attempting a catheter salvage, if the clinical situation allows it. 68 5 TIVAP removal is mandatory, regardless of the microbial etiology, in case of complicated 6
TIVAP-related infection defined by tunnel or port-pocket infections, severe sepsis or septic 7 shock, endocarditis, septic thrombophlebitis, osteomyelitis or other hematogenous seeding, as 8 suggested by IDSA guidelines (Figure 1 and 4) . 68 with uncomplicated LTIVC-related BSI due to CoNS (89%) or GNR (95%) ( Table 1) . 89,91,93 23 24
How to perform ALT? 25
No clinical trials have compared one drug to another and some in vitro studies have given 26 conflicting results with mitigated clinical relevance. 94,95 As described in Table 1 , more 27 frequently used antibiotics are glycopeptides, aminoglycosides or fluoroquinolones and their 28 use has been associated with high rates of therapeutic success. The chosen antibiotic must be 29 active in vitro against the identified microorganism. Ideally, antimicrobials should be 30 administered at a concentration at least 1000-fold above the minimal inhibitory concentration 31 (MIC) (frequently between 1 and 5 mg/mL) with a volume that fills the entire TIVAP lumen. 32
In most studies, ALT is prescribed for 10 to 14 days (Table 1 ) and the lock solution is usually 33 replaced every 12 to 24 hours, depending on the necessity for vascular access. 68 Replacing the 34 solution every 48 or 72 hours has also been performed safely. 93 In case of TIVAP-related BSI, 1 systemic antimicrobials should always be administered for 10 to 14 days. 68 Addition of 2 heparin in ALT has been proposed to avoid thrombosis of the catheter but no comparative 3 data support its use and adverse effects have been reported such as bleeding or the 4 enhancement of S. aureus biofilm formation in vitro. 96, 97 Therefore, ALT can be performed in 5 saline or heparin, at 10 to 100 IU/mL (Table 1) . 68 In case of conservative treatment, close 6 follow-up is mandatory to detect treatment failure and includes, at least, blood cultures 7 performed 3 days after the beginning of the treatment and 2-4 weeks after the end of the 8 treatment ( Figure 4) . Other preventive strategies are limited by the long-term implantation of TIVAP leading to 27 coverage by host blood components of any modified surface, and reduction of the effect of 28 antibiotic-coated catheters over time. One possible solution would be to use anti-adhesive 29 compounds inhibiting the deposition of blood components or inhibiting local thrombosis that 30 would delay or reduce the risk of formation of the protein film. For instance, a surface 31 modification using nonleaching polymeric sulfobetaine (polySB) is associated with a 32 significant reduction of adherence and activation of platelets and white blood cells. 115 This 33 scaffold retains water on the catheter surface and not only reduces proteins, host cells and 34 microbial adhesion but also thrombus formation in vitro and in vivo. 115 Although this and 1 other approaches provided encouraging results, they need to be assessed in long-term 2 settings. 116 3 4
Biofilm eradication inside TIVAP 5
Currently used antibiotics as lock therapy have drawbacks, such as possible treatment failure 6 or a long treatment duration. 68 Several investigators have attempted to develop more efficient 7 and faster ALT to face these challenges. In vitro and in vivo studies identified several 8 potential lock candidates and, for instance, ethanol or daptomycin are now being clinically 9 assessed. 94,103 Another approach is to use an adjuvant to increase antibiotic efficiency against 10 biofilms. For example, the association of an antibiotic and a chelator such as EDTA or citrate 11 has been proposed, since divalent cations play a key-role in maintaining biofilm matrix 12 stability. 117 Addition of chelators destabilize the matrix and therefore increase antimicrobial It has been demonstrated that the association of an aminoglycoside and a sugar such as 22 mannitol or fructose could increase antibiotic uptake in the most tolerant bacteria inside 23 biofilms called persister cells. Killing of persisters may lead to a more efficient treatment of 24 in vivo biofilms. 122 Such an approach could easily be converted to an ALT composed of an 25 aminoglycoside plus sugar. 26
As quorum sensing (QS) is a key component of biofilm communication, many investigators 27
have speculated that interfering with QS signals might alter biofilm maturation thereby 28 leading to easier eradication. For instance, RNAIII inhibiting peptide (RIP), a compound 29 interfering with S. aureus QS efficiently prevented CVC-related infection in vivo. 123 30
Another approach would be to favor bacterial biofilm dispersion as biofilm bacteria lose most 31 of their antibiotic tolerance when they return to a planktonic state. 33 However, the dispersal 32 approach needs to be associated with systemic and local antibiotics as released bacteria from 33 the biofilm into the bloodstream may express virulence genes and lead to severe sepsis. 124 
34
Many compounds such as dispersin B, DNase I or autoinducing peptides have been described 1 to favor biofilm dispersion in vitro, and to a lesser extent in vivo. 125 Thirty years of intense study of TIVAP-related infection epidemiology has led to an improved 2 delineation of patients at risk of infection, which is of key importance with regard to the 3 increasing number of inserted TIVAPs. Although ALT has proven to be a pivotal strategy for 4 the conservative treatment of selected uncomplicated TIVAP-related BSI, there is still much 5 work to be done, especially in light of recent experimental progresses made on reduction of 6 antimicrobial tolerance in TIVAP-associated infections using combinations of antibiotics and 7 antibiofilm compounds. It is also to be foreseen that preventive approaches will benefit from 8 device development specifically conceived to reduce microbial colonization and infection, for definitively answer this question. On the other hand, if the candidemia is CR, it is very likely 7 that catheter removal is required. For instance, a retrospective study including 404 patients 8 with cancer, CVC and candidemia identified after multivariate analysis that early catheter 9 removal improved response to antifungal therapy only among patients with CR 10 candidemia. 136 In this context, one major issue is that the diagnosis of fungal CRBSI without 11 catheter removal is still challenging due to poor clinical evaluation of paired blood cultures in 12 this setting. 72,74,75 13
In case of CR candidemia, even if catheter removal is recommended, many patients cannot 14 afford a CVC replacement because of their general condition. Therefore, antifungal lock 15 therapy has been proposed to increase the likelihood of biofilm eradication, based on the same 16 principles as ALT. 100 In vitro and in vivo studies reveal that against Candida biofilms: i) 17 azoles have poor activity; ii) lipid formulations of amphotericin B are more effective than 18 amphotericin B deoxycholate; and iii) echinocandins have excellent in vitro activity. 100 Non-19 antifungal lock therapy against Candida biofilms have also been proposed such as EDTA in 20 combination with antifungals or minocycline, ethanol, heparin and even highly concentrated 21 antibiotics like doxycyline. 100, [137] [138] [139] [140] Even if no comparative study is available, more than 20 22 patients were treated with various types of antifungal locks with an overall success rate of 23 77% with a publication bias that should be taken into account. 100 Hence, ethanol lock therapy 24 could be a promising candidate with eight successes among ten reported patients. 139, 140 Of 25 note, most of these published cases are of pediatric patients with the limitation of diagnostic 26 criteria, frequently based on blood cultures drawn from the CVC without any peripheral blood 27 culture. Studies of antifungal lock therapy specifically for TIVAP-associated fungal infections 28 are clearly needed. These sources of funding had no involvement in the preparation of this manuscript. 20
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